What Marvel Biosciences does

Marvel Biosciences Corp. is a Calgary, Alberta-based clinical-stage pharmaceutical biotechnology company developing synthetic derivatives of known drugs for neurodevelopmental and neurodegenerative disorders. The company's lead asset, MB-204, is a novel fluorinated analogue of Istradefylline — an adenosine A2A receptor antagonist originally approved for Parkinson's disease — being repositioned as a first-in-class treatment targeting social reward pathways for neuropsychiatric conditions including autism spectrum disorder, Rett syndrome, Fragile X syndrome, depression, and Alzheimer's disease. Preclinically, MB-204 significantly outperformed the approved Rett syndrome therapy trofinetide across multiple efficacy endpoints and has been formulated into two pediatric-friendly liquid dosage forms achieving 79% and 91% oral bioavailability in mouse studies, addressing a key unmet need for children with swallowing difficulties or feeding-tube dependence. The company has secured composition-of-matter patents in the United States, Japan, China, and Australia (allowed).

Marvel operates as a pre-revenue, publicly listed entity on the TSX Venture Exchange through its wholly-owned operating subsidiary Marvel Biotechnology Inc. Its go-to-market model is licensing- and partnership-driven: future revenue is expected through pharmaceutical out-licensing deals, co-development arrangements, or eventual commercialization following regulatory approval, with no current pricing or commercial products. The company is conducting its Phase I clinical trial in Australia through CRO partner Novotech, leveraging the country's R&D tax credits exceeding 40% of trial costs, and has assembled a lean capital stack combining non-dilutive grants (Alberta Innovates AICE, NRC IRAP), strategic investment (5 Horizon Ventures covering 15% of trial costs), private placements (approximately CAD $1 million issued in April 2026 at $0.125 per unit), and a CAD $500,000 unsecured convertible debenture (12% interest, maturing December 31, 2027). The company engages in business development through industry conferences and partnering summits, with Chief Science Officer Dr. Mark Williams presenting MB-204 at the 2nd Neuroscience Innovation Partnering & Licensing Summit in Boston in April 2026.

Name

Marvel Biosciences

Legal name

Marvel Biosciences Corp.

Website

https://marvelbiotechnology.com

Company type

Public

Founded year

2018

Operating status

Operating

Headcount range

1–10 employees

Short description

Marvel Biosciences is a Calgary-based clinical-stage biotech developing MB-204, a novel fluorinated adenosine A2A receptor antagonist for autism, Rett syndrome, Fragile X, depression, and Alzheimer's. Pre-revenue, with future revenue expected from pharmaceutical licensing deals.

Ownership category

akta.pro rank

Product category

Neurodevelopmental Therapeutics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Rare Neurology & Neurodegenerative Disorder Therapies (HLAIAIAD)

akta.pro secondary industries

Rare Pediatric & Congenital Disorder Therapies (HLAIAIAN), Neurology & Psychiatry (CNS) Pharmaceuticals (HLAIAAAF)

Keywords

• Adenosine receptor antagonists
• Neurodevelopmental therapeutics
• Clinical-stage biotechnology
• Central nervous system drugs
• Pediatric drug formulations

Headquarters

HQ city

Calgary

HQ country

Canada

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Operations, Personnel, Marketing or Sales

Revenue model

1. Drug Development and Licensing: Pre-revenue clinical stage biotech company. Future revenue expected through pharmaceutical licensing deals, co-development partnerships, or eventual product commercialization following successful clinical trials and regulatory approval.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels3 records

Core offering

Marvel Biosciences is developing MB-204, a novel fluorinated derivative of the FDA-approved Parkinson's drug Istradefylline, which acts as an adenosine A2A receptor antagonist. MB-204 is being advanced as a first-in-class treatment targeting social reward pathways for neurodevelopmental and neurodegenerative disorders including autism spectrum disorder, Rett syndrome, Fragile X syndrome, depression, and Alzheimer's disease, with pediatric-friendly oral liquid formulations.

Product overview

Marvel Biosciences is a Calgary-based preclinical-stage pharmaceutical biotechnology company focused on discovering and developing synthetic derivatives of known drugs for neurological and neurodevelopmental disorders. The company's primary product is MB-204, a novel fluorinated derivative of the FDA-approved anti-Parkinson's drug Istradefylline, which acts as a neuroactive adenosine A2A receptor antagonist. MB-204 is being developed as a potential first-in-class treatment for conditions including autism spectrum disorder, Rett syndrome, Fragile X syndrome, depression, and Alzheimer's disease. The company is advancing MB-204 through preclinical toxicology studies toward Phase I clinical trials, with multiple composition-of-matter patents granted across major jurisdictions including the US, Japan, China, and Australia.

Differentiator

Problem solved

Functional benefit

Products and services

• MB-204 MB-204 is a novel fluorinated derivative of Istradefylline (an adenosine A2A receptor antagonist) being developed as a first-in-class treatment targeting social reward pathways for neuropsychiatric disorders including autism spectrum disorder, Rett syndrome, Fragile X syndrome, depression, and Alzheimer's disease. In preclinical Rett syndrome models it significantly outperformed the approved therapy trofinetide across multiple efficacy endpoints. Pediatric-friendly oral liquid formulations achieving 79–91% oral bioavailability have been identified.

Quantifiable outcome

• MB-204 significantly outperformed the approved therapy trofinetide across multiple efficacy endpoints in Rett syndrome preclinical models
• +1 more outcomes

Segments6 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

Two partnerships are on record, tiered core and minor.

• NovotechcoreImplementation/ SI/ Consulting PartnerMarvel Biosciences selected Novotech as their contract research organization (CRO) to conduct the Phase I clinical trial of MB-204 in Australia. The trial will leverage Australia's favorable regulatory environment and tax credits exceeding 40% of costs, marking MB-204's transition into human trials.
• 3rd European Purine MeetingminorOthersMarvel Biosciences sponsors the 3rd European Purine Meeting in Bordeaux, France (June 30 - July 3, 2026). The event focuses on sharing new discoveries in purinergic system research, which is involved in diseases such as Alzheimer's and autism, with potential implications for future therapies.

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Anavex Life Sciences: Clinical-stage biotech developing ANAVEX 2-73 (blarcamesine) for Rett syndrome, Fragile X, and Alzheimer's - directly overlapping MB-204's indications and targeting rare pediatric neurodevelopmental populations.
• Acadia Pharmaceuticals: Acadia markets Daybue (trofinetide), the only FDA-approved therapy for Rett syndrome - the same indication where MB-204 demonstrated preclinical outperformance. Both companies target rare pediatric neurodevelopmental disorders with CNS-active molecules.
• Kyowa Kirin: Kyowa Kirin markets Nourianz (istradefylline), the FDA-approved A2A receptor antagonist from which Marvel's MB-204 is derived. Direct mechanistic and structural precedent for MB-204's A2A pharmacology.
• Newron Pharmaceuticals: European CNS-focused biotech that developed/develops therapies for Rett syndrome and other neurodevelopmental disorders, including partnerships with major pharma for CNS assets.
• Marinus Pharmaceuticals: Developed Ztalmy (ganaxolone) for CDKL5 deficiency disorder and other rare pediatric neurological epilepsies. Operates in the same rare pediatric neurodevelopment niche with FDA-approved CNS assets.

Broad incumbents

• Axsome Therapeutics: Commercial CNS specialty pharma with approved products in depression and migraine. Comparable specialty neurology/neuropsychiatry commercialization model for MB-204's depression and broader CNS indications.
• Intra-Cellular Therapies: CNS-focused commercial pharma (Caplyta for schizophrenia/depression) with parallel development model in neuropsychiatric indications where MB-204 is also being positioned.
• Sage Therapeutics: CNS therapeutics company (Zurzuvae for postpartum depression) with a development and commercialization footprint in the same neurology/psychiatry category where MB-204 is targeting depression and ASD.
• BioMarin Pharmaceutical: Established rare disease biotech with multiple approved rare pediatric therapies. Represents the typical strategic acquirer/licensor profile for a rare pediatric neurodevelopment asset like MB-204.

Emerging players

• Cerevel Therapeutics: Clinical-stage neuroscience company developing therapies for CNS disorders including Parkinson's and psychiatry - overlapping with MB-204's A2A mechanism and broader neurology positioning.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries1 record

Funding overview

Funding rounds7 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Marvel Biosciences